Compare · BIO vs PACB
BIO vs PACB
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Pacific Biosciences of California Inc. (PACB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and PACB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $6.92B, about 13.9x PACB ($496.8M).
- Over the past year, BIO is up 8.4% and PACB is up 40.4% - PACB leads by 32.0 points.
- PACB has been more active in the news (6 items in the past 4 weeks vs 3 for BIO).
- PACB has more recent analyst coverage (24 ratings vs 11 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- Pacific Biosciences of California Inc.
- Price
- $256.19-8.55%
- $1.60+0.63%
- Market cap
- $6.92B
- $496.8M
- 1M return
- -7.99%
- +19.40%
- 1Y return
- +8.38%
- +40.35%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2010
- News (4w)
- 3
- 6
- Recent ratings
- 11
- 24
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest BIO
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
- Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
- Bio-Rad's Management to Participate in Upcoming Investor Conferences
Latest PACB
- SEC Form DEFA14A filed by Pacific Biosciences of California Inc.
- SEC Form DEF 14A filed by Pacific Biosciences of California Inc.
- PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
- PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
- PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
- SEC Form 4 filed by Gibson Christopher
- SEC Form 4 filed by Gibson James R Ii
- Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.
- Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure